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Abstract
Background: The best catecholamine regimen for cardiogenic shock has been poorly evaluated. When a vasopressor is
required to treat patients with the most severe form of cardiogenic shock, whether inodilators should be added or whether
inopressors can be used alone has not been established. The purpose of this study was to compare the impact of these two
strategies on short-term mortality in patients with severe cardiogenic shocks.
Methods and Results: Three observational cohorts of patients with decompensated heart failure were pooled to comprise a
total of 1,272 patients with cardiogenic shocks. Of these 1,272 patients, 988 were considered to be severe because they
required a vasopressor during the first 24 hours. We developed a propensity-score (PS) model to predict the individual
probability of receiving one of the two regimens (inopressors alone or a combination) conditionally on baseline-measured
covariates. The benefit of the treatment regimen on the mortality rate was estimated by fitting a weighted Cox regression
model. A total of 643 patients (65.1%) died within the first 30 days (inopressors alone: 293 (72.0%); inopressors and
inodilators: 350 (60.0%)). After PS weighting, we observed that the use of an inopressor plus an inodilator was associated
with an improved short-term mortality (HR: 0.66 [0.55–0.80]) compared to inopressors alone.
Conclusions: In the most severe forms of cardiogenic shock where a vasopressor is immediately required, adding an
inodilator may improve short-term mortality. This result should be confirmed in a randomized, controlled trial.
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Introduction
Cardiogenic shock, which is characterized by inadequate tissue
perfusion in the presence of cardiac failure, is one of the leading
causes of hemodynamic instability in critically ill patients and is
associated with a high mortality rate [1]. Hemodynamic resusci-
tation aims at optimizing organ perfusion and avoiding the
evolution toward multiple organ failure. Optimized organ
perfusion relies on a cautious, limited volume fluid challenge that
is usually followed, in the case of persistent instability, by the
administration of inotropes [2]. Because blood pressure occasion-
ally fails to increase, vasopressors are often considered as the next-
step therapy [2]. However, vasopressors might alter peripheral
microcirculation [3] and increase left ventricular afterload [4].
Hence, two theories are encountered: 1) treatment should focus on
inotropic support and limitation of left ventricular afterload to
avoid any type of vasoconstriction [5]; and 2) similar to sepsis,
cardiogenic shock is rapidly associated with a systemic inflamma-
tory state that may require additional vasopressors to restore organ
perfusion [6].
The most frequently used vasopressors are norepinephrine,
epinephrine and high-dose dopamine [7,8]. All of these agents are
inopressors because they interact to different degrees with both the
alpha-adrenergic and beta-adrenergic receptors [9]. However, if
the gain in terms of inotropic activity is overweighed by the
increase in left ventricular afterload, the resultant cardiac output
may be decreased and organ perfusion may be further compro-
mised. Levy et al. [10] randomly compared epinephrine to
dobutamine plus norepinephrine in a small sample of patients
(n = 30) with cardiogenic shock. They showed that the global
hemodynamic effects of the two strategies were similar; however,
regional perfusion parameters, such as gastric mucosa perfusion,
may be improved by combined use of norepinephrine and
dobutamine.
The question of the best drug regimen in patients with severe
cardiogenic shock must be resolved. It is unclear whether
inodilators should be combined with inopressors when the latter
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are needed or whether inopressors can be used alone. In practice,
this question is frequently encountered when a patient fails to
improve although dobutamine has been administered. Should we
add norepinephrine to dobutamine or switch to epinephrine and
discontinue the dobutamine infusion? This question most likely
justifies the need for a large multicenter, randomized, controlled
trial. However, before designing such a trial, we should explore the
data derived from observational studies. Therefore, the goal of this
study was to assess, using a propensity-based analysis of
observational data, whether the initial regimen of pharmacological
hemodynamic therapy could impact short-term mortality in
patients with cardiogenic shock who require an inopressor.
Analysis
Study Design
The study relies on propensity-score (PS) analyses of three
pooled observational datasets. The reporting follows the checklist
proposed in the STROBE statement [11].
Cohorts and Data Sources
The data analyzed in this observational study were derived from
three registries of patients with acute heart failure: the ALARM-
HF cohort [8], the EFICA cohort [7] and the Czech registry of
acute heart failure – AHEAD [12]. Patients with cardiogenic
shock after a successfully resuscitated cardiac arrest were not
considered.
The ALARM-HF global survey (Acute Heart Failure Global
Registry of Standard Treatment) collected anonymous data from
4,953 patients originating from nine countries: France, Germany,
Italy, Spain, the United Kingdom, Greece, Turkey, Australia, and
Mexico [8]. The hospital sample was selected to represent various
categories relevant to geographic region, hospital size (number of
beds), sector (public vs. private) and type (university vs. nonteach-
ing status). The study was conducted as a retrospective, in-hospital,
observational survey via a questionnaire. The paper-based data
collection was conducted from October 2006 to March 2007. The
same patient was not allowed to be represented more than once.
Acute heart failure was the final diagnosis for all of the studied
patients based on the 2005 ESC/ESICM guidelines [13]. We
collected the type and the severity of cardiac decompensation, and
we identified patients who were classified as cardiogenic shock
(n = 520).
The EFICA (Etude Franc¸aise de l’Insuffisance Cardiaque Aigue) study
is an observational follow-up study of patients with severe acute
decompensated heart failure (excluding acute coronary syndromes)
who were admitted to a representative sample of 60 French units
randomly selected from a national registry of adult intensive care
units (ICUs) and coronary care units (approximately 500) in
public, semiprivate and private hospitals in France, which
commonly admit patients with severe heart failure [7]. The
purpose of this study was to investigate the clinical and etiologic
features of severe heart failure; to measure the impact of disease in
terms of length of hospital stay and of short- and long-term
mortality rates; and to evaluate the determinants of short- and
long-term survival. From April to October 2001, the 60
participating centers (18 university hospitals, 31 general hospitals
and 11 semiprivate and private hospitals) included 599 patients, of
whom 152 were considered to be patients with cardiogenic shock.
The Czech Acute Heart Failure Database (AHEAD) registry was
created to assess the basic characteristics, management and
outcome of patients with acute heart failure in the Czech Republic
[12]. The anonymous data from 674 patients with consecutive
cardiogenic shock were collected from September 2006 to October
2009. The AHEAD registry included consecutive patients from
seven centers with a 24-hour catheterization laboratory service
and centralized care for patients with acute coronary syndromes
(ACS) from a region of approximately three million inhabitants,
and from five regional hospitals without a catheterization
laboratory service. The participating centers were chosen to
represent various categories relevant to geographic region and
hospital type (university vs. nonteaching status). Cardiogenic shock
was also defined according to the 2005 ESC/ESICM guidelines
[13].
Ethical Issues
The studies were considered to be retrospective patient record
studies in which the patients and doctors participating were
anonymous prior to processing the data. The studies were
conducted according to the principles of the Declaration of
Helsinki and approved by national ethics committees (Comite´
Consultatif sur le Traitement de l’Information en Matie`re de
Recherche, Comite´ d’Ethique pour la Recherche Biome´dicale,
Ethics Committee of the Faculty Hospital Brno), which delivered a
waiver of informed consent. Additionally, the data treatment was
conducted in accordance with the ICC/ESOMAR code of
conduct governing market research, specifically the compliance
with the ‘‘safe harbor’’ rules and US HIPAA Privacy rule.
Concerning the EFICA cohort, a national review board (Comite´
consultatif sur le traitement de l’information en matie`re de
recherche, French Ministry of Research) approved the study.
Definition for Cardiogenic Shock
The definition used for cardiogenic shock in the ALARM-HF
study and the AHEAD registry was the one proposed in the
2005 ESC/ESICM guidelines [13]: evidence of tissue hypoperfu-
sion induced by heart failure after correction of preload,
characterized by a reduced blood pressure (systolic BP,90 mm
Hg or a drop of mean arterial pressure .30 mm Hg) and a low
urine output (,0.5 ml/kg/h), with a pulse rate .60 b.p.m. with
or without evidence of organ congestion. Because of the different
time periods, the criteria used for EFICA were slightly different.
However, in the EFICA study, all of the patients’ charts were
reviewed for the diagnosis of acute decompensated heart failure by
a steering committee composed of five senior cardiologists, two
senior intensive care specialists and three epidemiologists. Patients
who received assist devices and extracorporeal circulation and
postcardiac surgical patients were not included in the study.
Pooling the three studies led to a dataset of 1,346 patients with
cardiogenic shock. A total of 74 patients (5.5%) presenting one or
more missing data in the treatment regimen or outcome were
excluded from the analysis, leading to a total of 1,272 patients.
Among those patients, we focused on the 988 patients who
required an inopressor during the first 24 hours to achieve the
hemodynamic goals (Figure 1).
For each cohort, the number of patients was slightly different
from those previously published. Concerning the AHEAD cohort,
previous publications involved the main registry (two biggest
centers) [12], whereas we used the global registry. Concerning the
EFICA and the ALARM-HF cohorts, we excluded several patients
because of missing data in the treatment regimen or outcome.
Patient Evaluation
The following potential confounders or effect modifiers were
recorded in the three studies and included our analysis: age;
gender; New York Heart Association Classification (NYHA); first
systolic blood pressure (SBP); first heart rate (HR); first B-type
plasma natriuretic peptide concentration (BNP); first left ventric-
Inopressors and Mortality in Cardiogenic Shock
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ular ejection fraction (LVEF); first serum creatinine concentration
(serum creatinine); acute coronary syndrome (ACS); history of
renal disease (renal disease), diabetes mellitus, coronary artery
disease (CAD) or chronic heart failure (CHF); teaching hospital;
treatment with continuous positive airway pressure (CPAP); and
the presence of a prior cardiovascular treatment (beta blockers,
renin-angiotensin inhibitors, diuretics, and nitrates). Details of the
intravenous drugs administered for AHF, including timing and
duration, were also registered. For most variables, the proportion
of missing data for other variables was less than 10%. For missing
data concerning variables other than the treatment regimen, the
length of stay or the outcome, a multiple imputation procedure
was applied.
Drug Regimens
The following drugs were identified in the dataset: epinephrine,
norepinephrine, dopamine, dobutamine, levosimendan and phos-
phodiesterase III inhibitors. We classified these drugs according to
their action on the vascular tone. Hence, we differentiated two
different types of drugs: the inodilators, i.e., drugs associated with
inotropic and vasodilator activities (dobutamine, levosimendan
and phosphodiesterase III inhibitors), and the inopressors, i.e., drugs
associated with inotropic and inopressor activities (epinephrine,
Figure 1. Flowchart. Combined regimen stands for inopressors and inodilators; *patients excluded for missing data concerning the treatment
regimen, the outcome or the length of hospital stay; $patients included in the final analysis.
doi:10.1371/journal.pone.0071659.g001
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norepinephrine, and dopamine). The distribution of the initial
drug regimen was homogeneous across countries. In all of the
studies, the drugs were administered using continuous infusion.
The primary goal of the study was to investigate the effects of
treating cardiogenic shock patients with inopressors alone or with
inopressors and inodilators on short-term mortality. We defined and
compared the two regimens as follows: the inopressors alone and the
inopressors and inodilators (association of at least one inodilator with
an inopressor). Patients who received an inodilator alone were not
considered for the present analysis because they were usually less
severe than those who required an inopressor. In this study, we
focused on the initial drug regimen, corresponding to the drugs
received during the first 24 hours after the diagnosis of cardiogenic
shock.
Primary Outcome Measure
The patients were followed from their first day of admission
until day 30. The primary outcome measure was mortality up to
day 30. None of the 988 patients included in the final analysis
presented missing data on the primary outcome measure.
Statistical Methods
Continuous variables are presented as the mean (standard
deviation) or median (interquartile range) as appropriate, whereas
the categorical variables are presented as the number (percentage).
Because of the nonrandomized design, the two treatment groups
could not be considered to be exchangeable. The distribution of
baseline risk factors may have differed between the groups, and
several of them may bias the relationship between the treatment
and the outcome. To address this problem, we used a propensity
score approach [14]. The probability to receive either inopressors
alone or inopressors and inodilators was modeled using a nonparsimo-
nious (including all of the potential confounders/effect modifiers)
logistic regression model. The PS model calibration (Hosmer-
Lemeshow goodness-of-fit test) and discrimination performance
(area under the receiver operating curve) are provided in
Appendix S2. The individual propensity score derived from this
model was then used in an inverse probability of treatment
weighted (IPTW) analysis [15].
Mortality was modeled using Cox proportional hazards model.
Administrative censoring was applied on day 30 after admission.
Individual propensity scores were used to derive individual weights
defined as the inverse of the probability of receiving the treatment
actually received and used to weight the Cox regression [15]. The
balance in the baseline risk factors was evaluated in the original
and the weighted population by computing the standardized
differences (SD) [15]. The adequate balance was considered to be
achieved for standardized differences below 10% [16].
We included the participants with incomplete data in the
analysis using multiple imputations by chained equations with 30
imputations obtained after 10 iterations [17]. For all of the
variables except BNP and LVEF, the missing rate was less than
10%. The variables considered in the imputation models were all
baseline covariates, death status and Nelson-Aalen estimator of the
cumulative hazard at the time of death or censoring [18].
Treatment effect estimates and their standard errors were obtained
by pooling the estimates obtained on each imputed dataset
according to Rubin’s rules [19].
Several sensitivity analyses were performed. First, to evaluate the
impact of the missing data and the multiple imputation procedure,
we compared the results to those of a complete case analysis.
Because these two variables presented a higher rate of missing
values, we first excluded the BNP and the LVEF from the
propensity score model. We subsequently computed a complete
case analysis omitting these two variables. Therefore, all of the
patients presenting missing data on any of the variables used in the
propensity score model (other than BNP and LVEF) were
excluded from the analysis. This exclusion reduced the sample
size from 988 to 580. Second, we reran the analysis in the subgroups
of patients with and without acute coronary syndrome. Third, we
found 87 patients who received norepinephrine alone, which is not
usual in cardiogenic shock. We also reran the analysis after
discarding those patients. Finally, we reran the analysis in each
cohort separately.
The hazard ratios are expressed together with their 95%
confidence intervals. All tests were two-sided at the 0.05
significance level. We performed all of the analyses using R
software version 2.13 (http://www.R-project.org) running on a
Windows XP platform.
Results
Patient’s Characteristics
Pooling the 3 datasets led to an overall population of 1,346
patients with cardiogenic shock. Among these patients, 74 patients
were excluded for missing data concerning the treatment regimen,
the outcome or the length of hospital stay (Figure 1). Of the
remaining 1,272 patients, we focused on the most severe patients,
that is, 988 patients who required an inopressor during the first 24
hours. Their characteristics are summarized in Table 1.
The patients were essentially male (632 males, 64%) and older
than 60 years of age (n = 776, 78%). Before the acute episode,
approximately 30% of the patients were classified as NYHA grade
1 (n = 292, 29%), whereas the others were homogeneously
distributed over the other 3 grades of the classification. Approx-
imately half of the population (n= 570, 58%) presented an
underlying coronary artery disease; the most frequent reason for
cardiogenic shock was an acute coronary syndrome (n= 614,
62%). The patients were hypotensive (median systolic blood
pressure, 95 mmHg [80–120]) and tachycardic (median heart rate:
100 beats per minute (bpm) [80–120]). In most of the patients, the
B-type natriuretic peptide was elevated with a median of
1,009 pg/ml [356–3,228] and the left ventricular ejected fraction
was seriously altered (30% [23–40]). Patients’ characteristics
according to the cohort of origin are summarized in Appendix S1.
As a result of the nonrandomized design, the patients who
received inopressors alone were different from those who received
inopressors and inodilators with respect to baseline characteristics. As
illustrated by the standardized differences (Figure 2), those
differences were particularly important concerning the history of
kidney disease (SD=227.8%), the history of chronic heart failure
(SD=223.1%), the treatment with IABP (SD=218.3), gender
(SD=19.4%) or the first LVEF (SD=30.5%). However, after
weighting by the propensity score, all of the standardized
differences decreased below the 10% threshold, which suggested
that the propensity score weighting adequately handled the initial
selection bias (Figure 2 and Table 2).
Patients’ Outcomes
All 988 patients were followed up to day 30. A total of 643
patients (65%) died within the first 30 days: 73 patients (61%) in
the EFICA cohort, 424 patients (74%) in the AHEAD cohort and
146 patients (49%) in the ALARM-HF cohort. The effect of the
initial drug regimen on the original dataset was first studied
without any adjustment. The mortality rate highly differed
according to the treatment regimens: inopressors alone: 293 deaths
(72.0%) vs. inopressors and inodilators: 350 deaths (60.0%). Consis-
tently, the latter regimen was found to be associated with a
Inopressors and Mortality in Cardiogenic Shock
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Table 1. Patients’ characteristics and differences between the two treatment groups.
Overall Inopressors Alone Inopressors and Inodilators p
n=988 n=407 n=581
Patients’ Characteristics
Age Categories 0.048
#45 42 9 33
46–60 169 70 99
61–70 252 105 148
71–80 312 125 187
.80 212 98 114
Gender (male, %) 632 (64) 238 (58) 394 (68) 0.003
History
NYHA (I/II/III/IV) 292/267/225/204 130/120/92/65 167/147/133/139 0.029
CHF (%) 306 (31) 101 (25) 205 (35) ,0.001
CAD (%) 570 (58) 228 (56) 342 (59) 0.475
Renal Disease (%) 259 (26) 78 (19) 181 (31) ,0.001
Diabetes Mellitus (%) 396 (40) 150 (37) 246 (42) 0.104
Prior Treatment (%) 0.5211 0.443 0.839
Beta Blockers 299 (30) 115 (28) 184 (32)
ACEI/ARB 404 (41) 166 (41) 238 (41)
Diuretics 365 (37) 142 (35) 223 (38)
Nitrates 158 (16) 60 (15) 98 (17)
Characteristics at Baseline
SBP (mm Hg) 95 [80–120] 95 [80–120] 95 [80–120] 0.426
HR (bpm) 100 [80–120] 93 [75–120] 100 [80–120] 0.111
BNP (pg/ml) 1009 [356–3228] 611 [314–2358] 1280 [420–3475] 0.476
Serum Creatinine (mg/dl) 1.5 [1.1–2.1] 1.5 [1.1–2.1] 1.5 [1.1–2.1] 0.666
LVEF (%) 30 [23–40] 35 [25–45] 30 [20–40] ,0.001
Cause of Cardiogenic Shock
ACS (%) 614 (62) 262 (64) 352 (61) 0.254
Treatment
Inotropes/Vasoactive drugs (%) -
Epinephrine 464 (47) 234 (57) 230 (40)
Norepinephrine 611 (62) 251 (62) 360 (62)
Dopamine 384 (39) 142 (35) 242 (42)
Dobutamine 442 (45) 0 (0) 442 (76)
Levosimendan 96 (10) 0 (0) 96 (16)
Phosphodiesterase 3 Inhibitor 8 (1) 0 (0) 8 (1)
CPAP (%) 155 (16) 63 (15) 92 (16) 0.950
Mechanical Ventilation (%) 567 (57) 234 (57) 333 (57) 0.714
Primary PCI (%) 317 (32) 130 (32) 187 (33) 0.957
Teaching Hospital (%) 711 (72) 295 (72) 416 (72) 0.817
NYHA, New York Heart Association; ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, chronic heart failure; BNP, B-type natriuretic peptide; renal
disease, history of chronic renal failure; CPAP, continuous positive airway pressure; PCI, percutaneous coronary intervention ACEI/ARB, angiotensin-converting-enzyme
inhibitors/angiotensin II receptor blockers. The systolic blood pressure (SBP), the heart rate (HR), the BNP, the serum creatinine and the left ventricular ejection fraction
(LVEF) are presented as the median [IQR]. For categorical variables, the sum of the different categories might be inferior to the sample size because patients’
characteristics were analyzed from complete cases. The p values refer to the comparison of inopressors alone vs. inopressors and inodilators.
doi:10.1371/journal.pone.0071659.t001
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decrease in short-term mortality compared to the inopressors
alone regimen (HR: 0.61 [0.52–0.71]) (Figure 3, panel A).
The effect of the initial drug regimen on the mortality rate was
subsequently assessed among the weighted dataset. The details on
the propensity score model are provided in Appendix S2. After
weighting by the propensity score, the initial drug regimen was
strongly associated with short-term mortality; the regimen of
inopressors and inodilators performed better than the inopressors alone
regimen (HR: 0.66 [0.55–0.80]) (Figure 3, panel B).
Sensitivity Analyses
We reran the analyses after removing the two variables with the
higher rate of missing data from the propensity score model,
namely, the initial left ventricular ejection fraction and the initial
BNP. The results were not substantially modified. The regimen
inopressors and inodilators was associated with a decrease in short-
term mortality compared to the inopressors regimen (HR: 0.70
[0.59–0.83]). In the complete case analysis (n = 580), similar results
in terms of mortality were observed when we compared the
inopressors and inodilators regimen to the inopressors alone regimen (HR:
0.69 [0.56–0.86]).
As shown in Figure 4, the results remained unaltered when we
focused on the subgroups of patients with or without an acute
coronary syndrome (Figure 4). Similarly, discarding the 87 patients
who received norepinephrine alone did not further modify our
results (inopressors and inodilators vs. inopressors alone: HR: 0.60 [0.49–
0.73]). The results remained unaltered when we removed the
patients who received epinephrine alone (HR: 0.70 [0.54–0.92]).
Finally, the results remained unchanged when we analyzed each
cohort separately (Figure 4), except when the EFICA cohort was
analyzed alone. In the latter case, because of the small sample size,
the point estimate was similar but the confidence interval crossed
the unit.
Discussion
The impact of using inopressors in cardiogenic shock is still
open to discussion. In the sickest patients, blood pressure may fail
to increase after initial resuscitation (e.g., fluid challenge and
inotropes), prompting the use of an inopressor, as proposed by the
current international guidelines [2]. Inopressors may be justified
because prolonged hypotension could precipitate organ hypoper-
fusion, and especially decreased coronary perfusion pressure,
thereby increasing the risk of myocardial ischemia. Moreover, a
recent cardiogenic shock paradigm suggested that severe impair-
ments in cardiac function may be associated with systemic
inflammation and thus with a certain degree of vasodilatation
[6]. Inopressors might, in turn, alter peripheral microcirculation
[3], increase left ventricular afterload [4] and thus alter organ
perfusion. We used the data from 3 different observational cohorts
(ALARM-HF [8], EFICA [7] and AHEAD [12]) and compared
Figure 2. Standard differences in the major baseline covariates between the two treatment regimens. NYHA, New York Heart
Association; PCI, percutaneous intervention; IABP, intra-aortic balloon pump; CPAP, continuous positive airway pressure; HR, heart rate; BNP, B-type
natriuretic peptide; ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, chronic heart failure; ACEI/ARB, angiotensin-converting-
enzyme inhibitors/angiotensin II receptor blockers; BB, beta blockers; SBP, systolic blood pressure; LVEF, left ventricular ejection fraction.
doi:10.1371/journal.pone.0071659.g002
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inopressors alone to a combination of inopressors plus inodilators.
We found that using inopressors alone could be associated with a
greater short-term mortality compared to using a combined
regimen. This finding would suggest either that excessive
vasoconstriction is detrimental in patients with severe cardiogenic
shock or that vasodilation is beneficial. Because of the non-
randomized design, we cannot conclude that the patients who
received inopressors alone were sicker than those who received
inopressors and inodilators. However, the patients’ characteristics were
well balanced after propensity score weighting, and IPTW analysis
led to similar results.
Vasoconstriction per se could be considered to be potentially
harmful in this context. Excessive vasoconstriction may, in turn,
impair macro-hemodynamics by increasing left ventricular after-
load [4,20] and promoting myocardial oxygen delivery/oxygen
consumption imbalance [21]. Catecholamines have been advo-
cated to affect the restoration of cardiac function and increase
short- and long-term mortalities [22]. Excessive vasoconstriction
might also alter microcirculation [3]. Such a hypothesis has been
well documented in the context of septic shock [23,24]. In
cardiogenic shock, there are few data [25]; however, microvascu-
lar blood flow alterations are reportedly frequent and more severe
in patients who are not likely to survive [26]. However, the
detrimental effect of vasoconstriction might not be the only
explanation to support our results. The trial by De Backer et al.
[27] showed that a drug with a strong inotropic effect (dopamine)
could be deleterious compared to a potent vasopressor with a weak
inotropic activity (norepinephrine).
Vasodilation per se could be considered to be beneficial in this
context. Vasodilatation might preserve the microcirculation, organ
perfusion and likely the patient’s outcome. Such a hypothesis is
supported by the fact that applying low-dose nitroglycerin, in
addition to standard care for cardiogenic shock, has been shown to
result in an increase in sublingual perfused capillary density [28].
Our results are also consistent with the findings recently reported
by Levy et al. [10], which suggest that a combination of
norepinephrine-dobutamine might be more reliable and safer
than epinephrine in patients with cardiogenic shock. In their entire
cohort, Spinar et al. [12] reported an association between
norepinephrine infusion and in-hospital mortality. However,
inopressors are recommended and usually used because the
hemodynamic goals fail to be reached with the use of inotropes
Table 2. Patients’ characteristics and differences between the two treatment groups after PS weighting.
Inopressors Alone Inopressors and Inodilators p
n=407 n=581
Patients’ Characteristics
Age Categories (%) #45
46–60 61–70 71–80
.80
4.9
17.5 24.1 31.9 21.5
2.8 17.7 27.1 31.9 19.7 0.90
Gender (male, %) 36.3 37.2 0.81
History
NYHA (I/II/III/IV) (%) 30/27/20/22 29/28/24/18 0.87
CHF (%) 31.0 30.7 0.93
CAD (%) 57.6 60.1 0.48
Renal Disease (%) 26.3 26.9 0.86
Diabetes Mellitus (%) 40.3 41.5 0.75
Prior Treatment (%) Beta Blockers ACEI/ARB Diuretics
Nitrates
30.2 40.3 36.3 16.1 30.0 40.4 36.4 16.3 0.94 0.97 0.97 0.95
Characteristics at Baseline
SBP (mm Hg) 102 (32) 102 (33) 0.82
HR (bpm) 99 (30) 100 (32) 0.64
BNP (pg/ml) 2322 (2651) 2475 (2826) 0.50
Serum Creatinine (mg/dl) 1.9 (1.7) 1.9 (1.4) 0.88
LVEF (%) 33 (15) 33.4 (13.4) 0.97
Cause of Cardiogenic Shock
ACS (%) 62.5 65.2 0.44
Treatment
CPAP (%) 15.8 14.4 0.56
Mechanical Ventilation (%) 57.0 58.9 0.59
Primary PCI (%) 31.8 33.6 0.62
Teaching Hospital (%) 71.7 72.6 0.77
NYHA, New York Heart Association; ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, chronic heart failure; BNP, B-type natriuretic peptide; renal
disease, history of chronic renal failure; CPAP, continuous positive airway pressure; PCI, percutaneous coronary intervention ACEI/ARB, angiotensin-converting-enzyme
inhibitors/angiotensin II receptor blockers. The systolic blood pressure (SBP), the heart rate (HR), the BNP, the serum creatinine and the left ventricular ejection fraction
(LVEF) are presented as the median [IQR]. For categorical variables, the sum of the different categories might be inferior to the sample size because patients’
characteristics were analyzed from complete cases. The p values refer to the comparison of inopressors alone vs. inopressors and inodilators.
doi:10.1371/journal.pone.0071659.t002
Inopressors and Mortality in Cardiogenic Shock
PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e71659
alone. Combining our results with those of De Backer et al. [27]
would suggest that inopressors, such as norepinephrine, might be
necessary in severe patients, but the addition of a vasodilator might
be beneficial. These results might be considered to be conflicting
compared to several previous studies [29]. These conflicting results
could be explained by the differences in the study populations. For
instance, in OPTIME-CHF [30], the patients in shock were
excluded, whereas in the ADHERE registry [31], less than 3% of
the patients had low systolic blood pressure. Moreover, the
question we addressed was different. We focused on estimating the
benefit of adding a drug with vasodilator-related properties to
inopressors. Therefore, all of the patients in our cohort received
inopressors, which makes this population more severe. This point
is illustrated by the higher mortality rate in our cohort: On day 30,
Figure 3. Kaplan-Meier representation of mortality: A. As evaluated in the original pooled datasets; B. as evaluated in the pooled datasets
after PS weighting. (Combined regimen stands for inopressors and inodilators).
doi:10.1371/journal.pone.0071659.g003
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the mortality rate was 65% in our cohort, whereas it was 10.3% in
the milrinone group and 8.9% in the control group in OPTIME-
CHF, and 11% in the ICU/CCU group in the ADHERE registry.
Our study suffers several limitations. First, the lack of
randomization exposed to selection bias is a limitation. To handle
such a risk, we used a propensity score weighting approach
(IPTW) [15]. Second, several of the measured variables had a high
rate of missing data. We applied a multiple imputation algorithm
and controlled the results by performing a complete case analysis.
Third, we pooled various drugs to define the different treatment
regimens. However, two drugs defined as inopressors can have a
very different pharmacodynamic profile. Our goal was to assess
the impact of vasoconstriction on the prognosis; and this goal
could only be achieved by comparing the drugs with and without
inopressor activity. We were also concerned about the fact that
norepinephrine and epinephrine might have different effects on
patients with cardiogenic shock because epinephrine is a more
potent inotrope than norepinephrine. However, removing from
the analysis the patients who received norepinephrine alone did
not alter our results. Fourth, the enrollment period of the three
cohorts was long. However, studies on shock, either observational
or interventional, are difficult to perform and usually require long
inclusion periods. For instance, De Backer et al. included 1,679
shock patients in a 4-year period to complete their study [27].
Moreover, the guidelines for the management of cardiogenic shock
were not substantially modified during the last decade, and our
results were similar when we analyzed separately the older and the
more recent cohorts. Fifth, the definition of cardiogenic shock was
slightly different between EFICA and the other two registries.
However, in the EFICA study, all of the patients’ charts were
reviewed for the diagnosis of acute decompensated heart failure by
a steering committee; the diagnostic criteria that were applied did
not substantially change over the last decade. Moreover, the
results were consistent when analyzing the three cohorts separate-
ly. Sixth, the systolic blood pressure could be considered to be
surprisingly high. However, tissue hypoperfusion, rather than
systolic blood pressure, is the cornerstone of the diagnosis of shock
[2]. Hence, the mean blood pressure levels reported by De Backer
et al. [27] or Levy et al. [10] were 58 mm Hg and 55 mm Hg,
respectively, which is consistent with a systolic blood pressure of
approximately 90 mm Hg. Seventh, we did not record the drug dose
and were therefore unable to assess the presence of dose and
response relationships, which is essentially a problem for
dopamine, whose effects on vascular tones are dosage-dependent.
To further explore this potential source of bias, we performed a
complementary sensitivity analysis, which showed similar results
after excluding those patients who received dopamine (HR: 0.63
[0.50–0.80]). Finally, we only focused on initial treatment and
clinical parameters. We were unable to analyze the whole
treatment history or the evolution of hemodynamic profile under
treatment. Additional studies that consider the entire ICU stay will
therefore be warranted.
Our results may have important clinical implications. Our
findings support the concept that cardiogenic shock requires a
certain degree of vasodilation, although the macro-hemodynamics
prompt the use of vasopressors. Hence, in such a situation, we
should most likely prefer adding inopressors to inodilators and
monitor the results in terms of cardiac output and venous oxygen
saturation for a better optimization.
Conclusion
The initial use of inopressors alone appears to be associated with a
poorer prognosis compared to a regimen of inopressors and inodilators
in patients who are admitted for cardiogenic shock and who
require an inopressor during the first 24 hours. When an
inopressor is needed to achieve hemodynamic goals in patients
with cardiogenic shock, combining a drug with a vasodilating
activity might be useful. This result, based on observational data,
emphasizes the urgent need for a large multicenter, randomized,
controlled trial to compare those two regimens.
Supporting Information
Appendix S1 Patients’ characteristics according to the
cohort.
(DOCX)
Appendix S2 Propensity Score Model. Calibration as
evaluated by the Hosmer-Lemeshow statistic: X-squared = 8.91;
p = 0.444; discrimination as evaluated by the area under the
receiver operating curve: AUC-ROC=0.700.
(DOC)
Acknowledgments
Jiri Vitovec, Petr Widimsky, Ales Linhart, Jan Vaclavik, Jan Belohlavek,
Filip Malek, Cestmir Cihalik, Lenka Spinarova, Roman Miklik, Marian
Felsoci, Kamil Zeman and Etienne Gayat.
Author Contributions
Conceived and designed the experiments: RP. Performed the experiments:
RP AM. Analyzed the data: RP MRR. Contributed reagents/materials/
analysis tools: RP MRR SC AM JP JS JJ FZ FA. Wrote the paper: RP.
Read and approved the final manuscript: RP JP MRR SC JS JJ FZ FA
AM.
Figure 4. Subgroup PS-weighted analyses of the inopressors and
inodilators vs. inopressors alone on short-term mortality. HR,
hazard ratios; PS, propensity score; SBP, systolic blood pressure; ACS,
acute coronary syndrome.
doi:10.1371/journal.pone.0071659.g004
Inopressors and Mortality in Cardiogenic Shock
PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e71659
References
1. Krenn L, Delle Karth G (2011) Essential lessons in cardiogenic shock:
epinephrine versus norepinephrine/dobutamine. Crit Care Med 39: 583–584.
doi:10.1097/CCM.0b013e318208e381.
2. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bo¨hm M, et al. (2012)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart
failure 2012: The Task Force for the Diagnosis and Treatment of Acute and
Chronic Heart Failure 2012 of the European Society of Cardiology. Developed
in collaboration with the Heart Failure Association (HFA) of the ESC. Eur
Heart J 33: 1787–1847. doi:10.1093/eurheartj/ehs104.
3. Krejci V, Hiltebrand LB, Sigurdsson GH (2006) Effects of epinephrine,
norepinephrine, and phenylephrine on microcirculatory blood flow in the
gastrointestinal tract in sepsis. Crit Care Med 34: 1456–1463. doi:10.1097/
01.CCM.0000215834.48023.57.
4. Thompson RB, van den Bos EJ, Esposito DJ, Owen CH, Glower DD (2003)
The effects of acute afterload change on systolic ventricular function in conscious
dogs with normal vs. failing hearts. Eur J Heart Fail 5: 741–749.
5. Capomolla S, Pozzoli M, Opasich C, Febo O, Riccardi G, et al. (1997)
Dobutamine and nitroprusside infusion in patients with severe congestive heart
failure: hemodynamic improvement by discordant effects on mitral regurgita-
tion, left atrial function, and ventricular function. Am Heart J 134: 1089–1098.
6. Hochman JS (2003) Cardiogenic shock complicating acute myocardial
infarction: expanding the paradigm. Circulation 107: 2998–3002.
doi:10.1161/01.CIR.0000075927.67673.F2.
7. Zannad F, Mebazaa A, Juillie`re Y, Cohen-Solal A, Guize L, et al. (2006) Clinical
profile, contemporary management and one-year mortality in patients with
severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail 8:
697–705. doi:10.1016/j.ejheart.2006.01.001.
8. Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, et al. (2011) Short-term
survival by treatment among patients hospitalized with acute heart failure: the
global ALARM-HF registry using propensity scoring methods. Intensive Care
Med 37: 290–301. doi:10.1007/s00134-010-2073-4.
9. How O-J, Røsner A, Kildal AB, Stenberg TA, Gjessing PF, et al. (2010)
Dobutamine-norepinephrine, but not vasopressin, restores the ventriculoarterial
matching in experimental cardiogenic shock. Transl Res J Lab Clin Med 156:
273–281. doi:10.1016/j.trsl.2010.07.011.
10. Levy B, Perez P, Perny J, Thivilier C, Gerard A (2011) Comparison of
norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metab-
olism, and organ function variables in cardiogenic shock. A prospective,
randomized pilot study. Crit Care Med 39: 450–455. doi:10.1097/
CCM.0b013e3181ffe0eb.
11. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, et al. (2007) The
Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) statement: guidelines for reporting observational studies. Plos Med
4: e296. doi:10.1371/journal.pmed.0040296.
12. Spinar J, Parenica J, Vitovec J, Widimsky P, Linhart A, et al. (2011) Baseline
characteristics and hospital mortality in the Acute Heart Failure Database
(AHEAD) Main registry. Crit Care Lond Engl 15: R291. doi:10.1186/cc10584.
13. Nieminen MS, Bo¨hm M, Cowie MR, Drexler H, Filippatos GS, et al. (2005)
Executive summary of the guidelines on the diagnosis and treatment of acute
heart failure: the Task Force on Acute Heart Failure of the European Society of
Cardiology. Eur Heart J 26: 384–416. doi:10.1093/eurheartj/ehi044.
14. Paul R Rosenbaum, Rubin DB (1983) The central role of the propensity score in
observational studies for causal effects. Biometrika 70: 41–55.
15. Herna´n MA, Brumback B, Robins JM (2000) Marginal structural models to
estimate the causal effect of zidovudine on the survival of HIV-positive men.
Epidemiol Camb Mass 11: 561–570.
16. Austin PC (2009) Balance diagnostics for comparing the distribution of baseline
covariates between treatment groups in propensity-score matched samples. Stat
Med 28: 3083–3107. doi:10.1002/sim.3697.
17. White IR, Kalaitzaki E, Thompson SG (2011) Allowing for missing outcome
data and incomplete uptake of randomised interventions, with application to an
Internet-based alcohol trial. Stat Med 30: 3192–3207. doi:10.1002/sim.4360.
18. White IR, Royston P (2009) Imputing missing covariate values for the Cox
model. Stat Med 28: 1982–1998. doi:10.1002/sim.3618.
19. Rubin DB (1996) Multiple Imputation After 18+ Years. J Am Stat Assoc 91:
473–489.
20. Heusch G (1990) Alpha-adrenergic mechanisms in myocardial ischemia.
Circulation 81: 1–13.
21. Nikolaidis LA, Hentosz T, Doverspike A, Huerbin R, Stolarski C, et al. (2002)
Catecholamine stimulation is associated with impaired myocardial O(2)
utilization in heart failure. Cardiovasc Res 53: 392–404.
22. Reynolds HR, Hochman JS (2008) Cardiogenic shock: current concepts and
improving outcomes. Circulation 117: 686–697. doi:10.1161/CIRCULATIO-
NAHA.106.613596.
23. Palizas F, Dubin A, Regueira T, Bruhn A, Knobel E, et al. (2009) Gastric
tonometry versus cardiac index as resuscitation goals in septic shock: a
multicenter, randomized, controlled trial. Crit Care Lond Engl 13: R44.
doi:10.1186/cc7767.
24. Boerma EC, Koopmans M, Konijn A, Kaiferova K, Bakker AJ, et al. (2010)
Effects of nitroglycerin on sublingual microcirculatory blood flow in patients
with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind
randomized placebo controlled trial. Crit Care Med 38: 93–100. doi:10.1097/
CCM.0b013e3181b02fc1.
25. Jung C, Ro¨diger C, Fritzenwanger M, Schumm J, Lauten A, et al. (2009) Acute
microflow changes after stop and restart of intra-aortic balloon pump in
cardiogenic shock. Clin Res Cardiol Off J Ger Card Soc 98: 469–475.
doi:10.1007/s00392-009-0018-0.
26. De Backer D, Creteur J, Dubois MJ, Sakr Y, Vincent JL (2004) Microvascular
alterations in patients with acute severe heart failure and cardiogenic shock. Am
Heart J 147: 91–99.
27. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, et al. (2010)
Comparison of dopamine and norepinephrine in the treatment of shock.
N Engl J Med 362: 779–789. doi:10.1056/NEJMoa0907118.
28. Den Uil CA, Lagrand WK, Spronk PE, van der Ent M, Jewbali LSD, et al.
(2009) Low-dose nitroglycerin improves microcirculation in hospitalized patients
with acute heart failure. Eur J Heart Fail 11: 386–390. doi:10.1093/eurjhf/
hfp021.
29. Bayram M, De Luca L, Massie MB, Gheorghiade M (2005) Reassessment of
dobutamine, dopamine, and milrinone in the management of acute heart failure
syndromes. Am J Cardiol 96: 47G–58G. doi:10.1016/j.amjcard.2005.07.021.
30. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, et al. (2002) Short-
term intravenous milrinone for acute exacerbation of chronic heart failure: a
randomized controlled trial. Jama J Am Med Assoc 287: 1541–1547.
31. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, et al.
(2005) Characteristics and outcomes of patients hospitalized for heart failure in
the United States: rationale, design, and preliminary observations from the first
100,000 cases in the Acute Decompensated Heart Failure National Registry
(ADHERE). Am Heart J 149: 209–216. doi:10.1016/j.ahj.2004.08.005.
Inopressors and Mortality in Cardiogenic Shock
PLOS ONE | www.plosone.org 10 August 2013 | Volume 8 | Issue 8 | e71659
